Blood
The glycosaminoglycan oncofetal chondroitin sulfate represents a novel target for antibody drug-conjugate therapy for AML.
Joana Mujollari, Montserrat Estruch Alrich, Priya Khadgawat, Swati Choudhary, Tobias Gustavsson, Robert Dagil, Norbert Redlinger, Caroline Løppke, Elena Vidal Calvo, Mie Anemone Nordmaj, Thor Grundtvig Theander, Olaf Heidenreich, Yen Nguyen, Shuyu Qin, Anne Louise Tølbøll Sørensen
Published: 202510.1182/blood.2024028147
Abstract
Antibody-drug conjugates (ADCs) have emerged as promising targeted therapies in acute myeloid leukemia (AML). However, most ADCs exhibit off-target binding to normal hematopoietic stem and myeloid progenitor cells, resulting in adverse hemato-toxicit…
Preview only. Read the full abstract at the source